Shingrix: all 59 studies that test it

Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.

• A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk FactorsNot yet recruitingNCT07872046Phase 3
• A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in FinlandRecruitingNCT07502560Phase 4
• Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic DiseasesEnrolling by invitationNCT06763783Phase 4
• Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant RecipientsRecruitingNCT06262776Not applicable
• Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant RecipientsEnrolling by invitationNCT06162494Phase 4
• Immunogenicity, Reactogenicity of Shingrix in SLERecruitingNCT06001606Phase 3
• Shingrix In Recipients of Allogeneic TransplantsRecruitingNCT05775718Phase 2
• Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis PatientsRecruitingNCT05596526Phase 4
• Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control PopulationRecruitingNCT05580458Phase 1/2
• Safety of the Herpes Zoster Subunit Vaccine in LupusRecruitingNCT05559671Phase 4
• Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant RecipientsRecruitingNCT05554068Phase 2
• VZV in the Enteric Nervous System: Pathogenesis and ConsequencesRecruitingNCT05550194Phase 4
• Vaccine Responses in Patients With B Cell MalignanciesRecruitingNCT05170399Phase 4
• Shingrix in Renal Transplant RecipientsRecruitingNCT04128189Phase 3
• A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy AdultsCompletedNCT05966090Phase 3Results posted
• A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in IndiaCompletedNCT05219253Phase 3Results posted
• A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune ResponseCompletedNCT04176939Phase 3Results posted
• Persistence of Protection by ShingrixCompletedNCT04169009Phase 4Results posted
• Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes ZosterCompletedNCT04091451Phase 3Results posted
• Systems Biology of Zoster VaccineCompletedNCT04047979Phase 2Results posted
• Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix VaccineCompletedNCT03894969Phase 2Results posted
• Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With VedolizumabCompletedNCT03798691Phase 4Results posted
• Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)CompletedNCT03702231Phase 2Results posted
• Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on TofacitinibTerminatedNCT03591770Phase 4Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and OlderCompletedNCT03439657Phase 3Results posted
• Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of AgeCompletedNCT02979639Phase 3Results posted
• Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and OlderCompletedNCT02735915Phase 3Results posted
• A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older AdultsCompletedNCT02723773Phase 3Results posted
• Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.CompletedNCT02690207Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years EarlierCompletedNCT02581410Phase 3Results posted
• Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal TransplantCompletedNCT02058589Phase 3Results posted
• Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and OlderCompletedNCT02052596Phase 3Results posted
• Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and OlderCompletedNCT02045836Phase 3Results posted
• Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and OlderCompletedNCT01954251Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving ChemotherapyCompletedNCT01798056Phase 3Results posted
• Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 YearsCompletedNCT01777321Phase 3Results posted
• Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or OlderCompletedNCT01751165Phase 3Results posted
• Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173ACompletedNCT01610414Phase 3Results posted
• Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and OlderCompletedNCT01165229Phase 3Results posted
• Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected SubjectsCompletedNCT01165203Phase 2Results posted
• Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and OlderCompletedNCT01165177Phase 3Results posted
• Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173ACompletedNCT00920218Phase 2Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 YearsCompletedNCT00802464Phase 2Results posted
• Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and DementiaActive, not recruitingNCT07485283Phase 4
• Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveActive, not recruitingNCT07285265Phase 1
• Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and OverActive, not recruitingNCT06569823Phase 1/2
• A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 YearsCompletedNCT05991427Phase 1
• Phase I Clinical Trial of a Candidate Herpes Zoster VaccineStatus unknownNCT05718037Phase 1
• Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched ControlsActive, not recruitingNCT05575830Phase 4
• A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older AdultsActive, not recruitingNCT05371080Phase 3
• Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCTWithdrawnNCT04748939Phase 4
• Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home ResidentsCompletedNCT04523246Early Phase 1
• Recombinant Zoster Vaccine in Stable SLE PatientsStatus unknownNCT04516408Not applicable
• VZV-specific Tissue Resident Memory T-cells After Shingrix VaccinationActive, not recruitingNCT04403139Phase 4
• A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy ParticipantsCompletedNCT03953196Early Phase 1
• Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)CompletedNCT03886038Phase 4
• The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using AbataceptCompletedNCT03604406Phase 2
• Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year OldsCompletedNCT02114333Phase 1
• Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese AdultsCompletedNCT01086449Phase 1

← Shingrix overview